Hypera Strikes Takeda Deal To Dominate Brazil's OTC Market

Brazil's Hypera is paying Takeda $0.8bn for a portfolio of brands which will make it the "undisputed leader" in the South American country's OTC market. 

Hands holding rope forming arrow pointing upwards - Image
• Source: Shutterstock

[Hypera Pharma SA] is shoring up its position as the dominant player in Brazil’s consumer healthcare market by striking a deal to acquire a portfolio of OTC and Rx drugs from Japan’s Takeda Pharmaceutical Co. Ltd. for $825m. The transaction is expected to close by the end of 2020.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Latin America

More from Geography